Weight Loss Peptides: The Complete Guide for 2026

If you've been paying attention to health news lately, you've probably heard about peptides for weight loss. Ozempic, Wegovy, Mounjaro — these drugs have completely changed how doctors treat obesity. But they're just the tip of the iceberg.

In this guide, we'll break down every major weight loss peptide — from FDA-approved medications to research compounds. You'll learn how each one works, how they compare, what the science actually says, and what to watch out for.

Important: This guide is for educational purposes only. Peptides are powerful compounds that should only be used under medical supervision. Never self-administer prescription medications.

---

How Weight Loss Peptides Work

Before we dive into specific peptides, let's understand the basic science. Your body has several hormone systems that control hunger, fullness, and how you burn energy. Weight loss peptides tap into these systems.

The GLP-1 System

The biggest breakthrough in weight loss peptides involves a hormone called GLP-1 (glucagon-like peptide-1). Here's what it does:

• Tells your brain you're full. GLP-1 acts on appetite centers in the brain, reducing hunger signals.
• Slows down your stomach. Food stays in your stomach longer, so you feel satisfied after eating less.
• Helps control blood sugar. GLP-1 tells your pancreas to release insulin when blood sugar rises, which prevents the spikes and crashes that trigger cravings.
• May reduce food reward. Some research suggests GLP-1 drugs reduce the "pleasure" response to high-calorie foods.

Your body naturally makes GLP-1 after you eat, but it breaks down within minutes. Weight loss peptides are engineered to last much longer — days or even weeks.

The GIP System

GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone. For years, scientists thought GIP mostly just helped with blood sugar. But newer research shows it also plays a role in fat metabolism and appetite. Some of the newest weight loss peptides target both GLP-1 and GIP receptors at the same time.

Growth Hormone Pathways

A different class of peptides works through growth hormone (GH). These don't directly suppress appetite. Instead, they help your body burn fat for energy and preserve muscle mass. They work differently from GLP-1 drugs and are mostly used in research settings.

---

The Big Five: Weight Loss Peptides Explained

1. Semaglutide (Ozempic, Wegovy, Rybelsus)

What it is: A GLP-1 receptor agonist — meaning it mimics the GLP-1 hormone but lasts much longer in your body (about one week per dose).

FDA Status: ✅ Fully approved for both type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Also available as an oral tablet (Rybelsus, and the newer oral Wegovy formulation).

How it works: Semaglutide binds to GLP-1 receptors throughout your body. In the brain, it reduces appetite. In the gut, it slows digestion. In the pancreas, it improves blood sugar control.

What the research says:

The landmark STEP trials are the gold standard for semaglutide weight loss data:

• STEP 1 (2021): Adults with obesity lost an average of 14.9% of body weight over 68 weeks on semaglutide 2.4 mg weekly, compared to 2.4% with placebo. That's about 35 pounds for a 230-pound person. (Wilding et al., NEJM, 2021)
• STEP 3: When combined with intensive behavioral therapy (diet counseling, exercise plans), weight loss reached 16% of body weight.
• STEP 5: Over two years of treatment, participants maintained an average weight loss of 15.2%.
• SELECT trial (2023): In people with heart disease, semaglutide reduced the risk of heart attacks, strokes, and cardiovascular death by 20% — even independent of weight loss. (Lincoff et al., NEJM, 2023)

Dosing overview:

Semaglutide is typically started at a low dose and gradually increased over 16-20 weeks:

This slow titration helps minimize nausea and GI side effects.

Common side effects: Nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%), and stomach pain (20%). These are usually worst during dose increases and improve over time.

Serious risks: Pancreatitis (rare), gallbladder problems, potential thyroid tumor risk (seen in rodents, not confirmed in humans — carries a boxed warning).

Cost: $1,000-1,350/month without insurance for brand-name Wegovy. Compounded versions are being restricted — read our article on the 2026 compounded semaglutide ban for details.

👉 Read our detailed semaglutide guide →

---

2. Tirzepatide (Mounjaro, Zepbound)

What it is: A dual GLP-1/GIP receptor agonist. It activates both the GLP-1 and GIP hormone pathways simultaneously — the first drug of its kind.

FDA Status: ✅ Approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).

How it works: By hitting two receptors instead of one, tirzepatide gets a double effect. The GLP-1 component suppresses appetite and slows digestion (just like semaglutide). The GIP component adds additional metabolic benefits — improving how your body handles fat and potentially enhancing the weight loss effect beyond what GLP-1 alone can do.

What the research says:

The SURMOUNT trials showed tirzepatide produces more weight loss than any previous medication:

• SURMOUNT-1 (2022): Adults with obesity lost an average of 20.9% of body weight on the highest dose (15 mg) over 72 weeks. One-third of participants lost more than 25% of their body weight. (Jastreboff et al., NEJM, 2022)
• SURMOUNT-2: In people with both obesity and type 2 diabetes, weight loss averaged 14.7% on the highest dose.
• SURMOUNT-3: Combined with intensive lifestyle changes, weight loss reached a remarkable 26.6%.
• SURMOUNT-4: Showed that stopping tirzepatide leads to significant weight regain — participants regained about half the lost weight within a year of stopping.

Dosing overview:

Common side effects: Similar to semaglutide but generally milder in head-to-head comparisons. Nausea (up to 33%), diarrhea (23%), decreased appetite (20%), vomiting (12%).

Serious risks: Same class warnings as semaglutide — pancreatitis, gallbladder disease, thyroid tumors (animal studies).

How it compares to semaglutide: In the SURPASS trials (for diabetes), tirzepatide consistently outperformed semaglutide in both weight loss and blood sugar control. No head-to-head obesity trial has been published yet, but the numbers are clear: tirzepatide produces about 5-6% more total body weight loss on average.

Cost: $1,000-1,100/month without insurance for brand-name Zepbound.

---

3. AOD-9604

What it is: A modified fragment of human growth hormone (specifically, amino acids 177-191). It was designed to have the fat-burning effects of growth hormone without the muscle-building or blood sugar side effects.

FDA Status: ❌ Not FDA-approved for any indication. Classified as a research peptide. However, it has GRAS (Generally Recognized as Safe) status from the FDA as a food supplement ingredient.

How it works: AOD-9604 mimics the way natural growth hormone breaks down fat. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat creation). Unlike full growth hormone, it doesn't affect blood sugar levels or promote growth of muscles and organs.

The peptide works by:
- Activating beta-3 adrenergic receptors on fat cells
- Increasing the release of stored fat into the bloodstream
- Reducing the creation of new fat cells
- Not affecting IGF-1 levels (so no growth hormone side effects)

What the research says:

The evidence for AOD-9604 is much thinner than for semaglutide or tirzepatide:

• Early clinical trials (2000s): A Phase 2 trial in obese adults showed modest weight loss (about 2.8 kg more than placebo over 12 weeks) with oral AOD-9604. Results were described as "promising but not dramatic."
• Metabolic Pharmaceuticals originally developed AOD-9604 but abandoned it after Phase 2 results were underwhelming compared to expectations.
• Animal studies have shown more impressive results — significant fat reduction in obese mice and rats without affecting food intake.
• Safety data is actually reasonable — clinical trials showed no significant adverse effects, and the FDA granted GRAS status.

Typical research protocols: AOD-9604 is usually administered as a subcutaneous injection at 250-300 mcg per day, often taken in the morning on an empty stomach. Some protocols use it in cycles of 12 weeks on, 4 weeks off.

The bottom line: AOD-9604 is one of those "makes sense in theory" peptides. The mechanism is sound, and it appears safe. But the weight loss results in humans are modest at best. It doesn't come close to the dramatic results seen with GLP-1 drugs. Most people interested in this peptide are looking for something with fewer side effects than semaglutide, even if the results are smaller.

---

4. MOTS-c

What it is: A mitochondrial-derived peptide — a small signaling molecule encoded in your mitochondrial DNA. MOTS-c is sometimes called an "exercise mimetic" because it activates some of the same metabolic pathways as physical exercise.

FDA Status: ❌ Not FDA-approved. This is a research compound with limited human data.

How it works: MOTS-c primarily works through the AMPK pathway — the same energy-sensing system that exercise activates. Here's what it does:

• Activates AMPK — This is the master switch for cellular energy use. When AMPK is on, your cells burn more fat and glucose for energy.
• Improves insulin sensitivity — Helps your cells respond better to insulin, which means better blood sugar control and less fat storage.
• Enhances mitochondrial function — Your mitochondria are the energy factories in your cells. MOTS-c helps them work more efficiently.
• Promotes fatty acid oxidation — Encourages your body to burn fat as fuel.
• Reduces inflammation — Chronic inflammation is linked to obesity and metabolic disease. MOTS-c appears to have anti-inflammatory effects.

Think of it this way: while GLP-1 drugs work mostly by reducing how much you eat, MOTS-c works by changing how your body uses the energy from what you eat.

What the research says:

• Mouse studies (Lee et al., 2015): The original discovery paper showed that MOTS-c prevented diet-induced obesity in mice and improved insulin sensitivity. Mice on a high-fat diet that received MOTS-c gained significantly less weight. (Cell Metabolism, 2015)
• Human observational studies: People with naturally higher MOTS-c levels tend to be leaner and more metabolically healthy. MOTS-c levels decrease with age, which may partly explain age-related weight gain.
• Exercise studies (2020): Research showed that MOTS-c levels increase after exercise, and the peptide may be one of the signals that produces exercise's metabolic benefits. (Reynolds et al., JASN, 2020)
• Small human trials: Limited clinical data exists. Some preliminary studies suggest MOTS-c can improve insulin sensitivity in humans, but large-scale weight loss trials haven't been conducted.

Typical research protocols: MOTS-c is usually administered via subcutaneous injection at 5-10 mg per day, though protocols vary widely due to limited clinical guidance. Some researchers use it in 4-week cycles.

The bottom line: MOTS-c is fascinating science but early-stage for weight loss. It works through completely different mechanisms than GLP-1 drugs, which makes it potentially interesting as a complementary approach. However, the lack of large human trials means we don't know if it produces meaningful weight loss in people. It's best thought of as a metabolic optimizer rather than a primary weight loss tool.

---

5. Tesamorelin (Egrifta)

What it is: A growth hormone-releasing hormone (GHRH) analog. It stimulates your pituitary gland to produce more natural growth hormone.

FDA Status: ✅ Approved, but only for one specific condition — reducing excess abdominal fat (lipodystrophy) in HIV-positive adults on antiretroviral therapy.

How it works: Tesamorelin is a 44-amino-acid peptide that mimics your body's natural GHRH. When injected, it tells your pituitary gland to release growth hormone. The increased growth hormone then:

• Stimulates lipolysis — Breaks down stored fat, especially visceral (belly) fat.
• Reduces triglycerides — Lowers fat levels in the blood.
• Preserves lean muscle — Growth hormone helps maintain muscle mass during fat loss.
• May improve liver fat — Some research suggests it reduces non-alcoholic fatty liver disease (NAFLD).

The key advantage of tesamorelin over direct growth hormone injections is that it works through your body's natural feedback system. Your pituitary still controls the release, so you're less likely to get dangerously high GH levels.

What the research says:

• Phase 3 trials for HIV lipodystrophy: Tesamorelin reduced visceral fat (the dangerous fat around your organs) by an average of 15-18% over 26 weeks. Subcutaneous fat was relatively unaffected. (Falutz et al., NEJM, 2007)
• NAFLD studies: A 2019 study showed tesamorelin reduced liver fat by 37% in HIV patients with fatty liver disease, compared to a 10% increase in the placebo group. (Stanley et al., Lancet HIV, 2019)
• Cardiovascular markers: Tesamorelin improved several heart disease risk factors including triglycerides, cholesterol ratios, and C-reactive protein (a marker of inflammation).
• Body composition: While total body weight changes were modest (about 2-3 kg), the composition change was significant — less visceral fat and preserved lean mass.

Dosing: The FDA-approved dose is 2 mg injected subcutaneously once daily.

Common side effects: Injection site reactions (pain, redness, itching), joint pain, swelling in hands/feet, muscle pain, numbness/tingling. These are mostly related to increased growth hormone levels.

Serious risks: May worsen pre-existing cancers (growth hormone can stimulate cell growth), fluid retention, carpal tunnel syndrome, elevated blood sugar.

The bottom line: Tesamorelin is unique because it specifically targets visceral fat — the most dangerous type that wraps around your organs. It won't produce the dramatic scale changes of semaglutide or tirzepatide, but it changes where you carry fat, which matters for health. Its FDA approval (even if narrow) means it has real clinical data backing it up. The catch: it's only approved for HIV lipodystrophy, so off-label use for general weight loss is common but not officially sanctioned.

---

Head-to-Head Comparison

Here's how these five peptides stack up against each other:

*Semaglutide can cause significant lean mass loss — up to 40% of total weight lost may be muscle. Adding resistance training is strongly recommended.

---

Safety Considerations

Universal Risks of Weight Loss Peptides

No matter which peptide you're considering, keep these risks in mind:

Muscle loss. Rapid weight loss from any cause — peptides, surgery, or crash diets — can lead to significant muscle loss. A 2024 study found that about 40% of weight lost on semaglutide was lean mass (Heymsfield et al., Obesity, 2024). This is why doctors increasingly recommend:
- Resistance training (lifting weights) at least 2-3 times per week
- High protein intake (1.0-1.2 g per kg of body weight daily)
- Slow, gradual dose titration

Gallbladder problems. Rapid weight loss increases the risk of gallstones, regardless of the method. This is a particular concern with GLP-1 drugs due to the amount of weight lost. Symptoms include sudden severe pain in the upper right abdomen — seek medical attention immediately.

GI side effects. Nausea, vomiting, diarrhea, and constipation are extremely common with GLP-1 drugs, especially during dose titration. These usually improve over time but can be severe enough that some people discontinue treatment.

Rebound weight gain. The SURMOUNT-4 trial showed clearly: when you stop taking these peptides, the weight comes back. After one year off tirzepatide, participants regained about half the weight they'd lost. This suggests most people will need long-term treatment.

Mental health. Some reports link GLP-1 drugs to mood changes, including depression and suicidal thoughts. The FDA is investigating but hasn't confirmed a causal link. If you experience mood changes, tell your doctor.

Drug Interactions

GLP-1 drugs slow stomach emptying, which can affect how quickly other medications are absorbed. This is especially important for:
- Oral contraceptives — May be less effective. Use backup contraception during dose changes.
- Diabetes medications — Risk of dangerously low blood sugar when combined with insulin or sulfonylureas.
- Blood thinners — Absorption timing may change; more frequent monitoring needed.

Who Should NOT Use Weight Loss Peptides

• People with a personal or family history of medullary thyroid cancer or MEN2 syndrome
• People with a history of pancreatitis
• Pregnant or breastfeeding women
• People with severe gastroparesis (stomach paralysis)
• Anyone under 18 (limited pediatric data, though semaglutide was recently approved for teens 12+)

---

Practical Considerations

Getting a Prescription

For FDA-approved peptides (semaglutide, tirzepatide), you'll need a doctor's prescription. Options include:

1. Your primary care doctor — Many are now comfortable prescribing these medications for obesity.
2. Endocrinologists — Specialists in hormones and metabolism.
3. Obesity medicine specialists — Board-certified in weight management.
4. Telemedicine platforms — Several online platforms now prescribe GLP-1 medications after a virtual consultation. Read our telemedicine guide →

Most prescribers require a BMI of 30+ (or 27+ with a weight-related health condition like high blood pressure or type 2 diabetes).

Insurance Coverage

Coverage is improving but still inconsistent:
- Wegovy and Zepbound (weight loss indications) are covered by some insurers, but many still exclude weight loss medications.
- Ozempic and Mounjaro (diabetes indications) have broader coverage if you have type 2 diabetes.
- Medicare began covering anti-obesity medications in 2025 after legislative changes.
- Manufacturer savings programs can reduce out-of-pocket costs significantly.

Research Peptides: Sourcing and Safety

For non-FDA-approved peptides like AOD-9604 and MOTS-c, sourcing is a critical concern:

• These are typically sold as "research chemicals" — not intended for human use.
• Quality varies enormously between vendors. Always check for third-party testing and Certificates of Analysis (COA). Learn how to read a COA →
• The peptide vendor landscape is changing rapidly. Read about why vendors are closing →
• Never use research peptides without understanding the legal implications. Read our legal guide →

---

Emerging Weight Loss Peptides to Watch

The pipeline is full of next-generation compounds:

Retatrutide

A triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trial data showed up to 24.2% body weight loss over 48 weeks — potentially the most effective weight loss drug ever tested. Phase 3 trials are underway with results expected in 2026.

Orforglipron

An oral, non-peptide GLP-1 drug from Eli Lilly. Phase 3 trials are ongoing. If approved, it would be a daily pill instead of a weekly injection — potentially a game-changer for people who hate needles.

Survodutide

A dual GLP-1/glucagon agonist from Boehringer Ingelheim. Phase 2 data showed about 19% weight loss over 46 weeks. Also showing promise for fatty liver disease (MASH/NASH).

CagriSema

Novo Nordisk's combination of semaglutide with cagrilintide (an amylin analog). Phase 3 trials are showing weight loss potentially exceeding tirzepatide.

---

Frequently Asked Questions

How fast do weight loss peptides work?

GLP-1 drugs typically suppress appetite within the first week. Noticeable weight loss usually begins within 2-4 weeks. Maximum effect is reached at 6-12 months, depending on the drug and dose. Research peptides like AOD-9604 and MOTS-c are slower and less predictable.

Can I take multiple weight loss peptides at the same time?

Combining FDA-approved GLP-1 drugs is not recommended — they work on the same receptors and doubling up increases side effects without clear benefit. Some researchers have explored combining GLP-1 drugs with growth hormone peptides (like tesamorelin) to preserve muscle mass, but this is not established practice.

Will I regain the weight if I stop?

The evidence strongly suggests yes. The STEP 1 extension trial showed that participants regained two-thirds of their lost weight within one year of stopping semaglutide. The SURMOUNT-4 trial showed similar results with tirzepatide. Current medical consensus is that obesity is a chronic disease requiring ongoing treatment.

Are compounded versions safe?

Compounded semaglutide and tirzepatide have been popular lower-cost alternatives, but the landscape is changing. The FDA has been cracking down on compounded versions as brand-name supply has stabilized. If you do use a compounding pharmacy, ensure it's a 503B outsourcing facility (FDA-registered) rather than a 503A pharmacy.

Do weight loss peptides affect fertility?

Weight loss itself can improve fertility in people with obesity-related infertility. However, GLP-1 drugs should be stopped at least 2 months before trying to conceive (animal studies showed developmental risks). Improved ovulation after weight loss can also mean unexpected pregnancy — use contraception if needed.

What about peptides for weight loss in bodybuilding?

In fitness communities, peptides like AOD-9604, CJC-1295, and ipamorelin are popular for "cutting" phases. However, the evidence for these is much weaker than for GLP-1 drugs. Many bodybuilders now use low-dose semaglutide (0.25-0.5 mg/week) for fat loss while using resistance training and high protein intake to preserve muscle.

---

The Bottom Line

Weight loss peptides are one of the most significant medical advances of our time. Semaglutide and tirzepatide have proven that safe, effective pharmacological weight loss is possible — something doctors have been chasing for decades.

Here's the honest breakdown:

• If you need significant weight loss and have access to healthcare, semaglutide or tirzepatide are the clear winners. They have the strongest evidence, FDA approval, and the most dramatic results.
• If you're specifically concerned about visceral fat and have a doctor willing to prescribe off-label, tesamorelin is worth discussing.
• If you're interested in metabolic optimization beyond weight loss, MOTS-c is scientifically interesting but still early-stage.
• If you want something with minimal side effects and are okay with modest results, AOD-9604 has a decent safety profile but limited weight loss data.

Whatever path you choose, remember: peptides work best as part of a comprehensive approach that includes proper nutrition, regular exercise (especially resistance training), adequate sleep, and ongoing medical supervision.

---

References

1. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183

2. Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038

3. Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." New England Journal of Medicine. 2023;389(24):2221-2232. DOI: 10.1056/NEJMoa2307563

4. Lee C, et al. "The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance." Cell Metabolism. 2015;21(3):443-454. DOI: 10.1016/j.cmet.2015.02.009

5. Falutz J, et al. "Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV." New England Journal of Medicine. 2007;357(23):2359-2370. DOI: 10.1056/NEJMoa072375

6. Stanley TL, et al. "Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients with Abdominal Fat Accumulation." Lancet HIV. 2019;6(3):e154-e163.

7. Heymsfield SB, et al. "Weight Loss Composition is One-Fourth Fat-Free Mass." Obesity. 2024. DOI: 10.1002/oby.23932

8. Aronne LJ, et al. "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4)." JAMA. 2024;331(1):38-48. DOI: 10.1001/jama.2023.24945

9. Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity." New England Journal of Medicine. 2023;389(6):514-526. DOI: 10.1056/NEJMoa2301972

10. Rubino DM, et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance." JAMA. 2021;325(14):1414-1425. DOI: 10.1001/jama.2021.3224